Understanding and targeting abnormal hormone production in prostate cancer without CHD1.
Official title: Mechanism and therapeutic targeting of abnormal androgenesis in CHD1-deficient prostate cancer
Funded at Mayo Clinic Rochester · NIH-11067794 · Data updated 2026-11-12
This study is looking at how the missing CHD1 gene in prostate cancer affects hormone production and treatment resistance, with the goal of finding new ways to help patients with advanced prostate cancer feel better and respond to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | April 5, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $452,180 |
| NIH project number | 5R01CA286864-02 |
| Project ID | NIH-11067794 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those with CHD1 gene deletions or resistance to androgen receptor inhibitors.
✕Less likely to help
Patients with early-stage prostate cancer or those whose cancer is not driven by androgen receptor signaling may not benefit from this research.
What this research studies
This research investigates how the loss of the CHD1 gene affects hormone production in prostate cancer, leading to resistance against common treatments. It focuses on the role of abnormal androgen synthesis within tumors and how this contributes to the progression of the disease. By examining the interactions between CHD1 and other proteins, the study aims to uncover new therapeutic targets that could improve treatment outcomes for patients with advanced prostate cancer. The approach includes analyzing genetic and biochemical pathways involved in hormone synthesis and resistance mechanisms.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced prostate cancer who currently have limited options due to treatment resistance.
How similar studies have gone: Previous research has shown promising results in targeting androgen receptor signaling in prostate cancer, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Domingo-Domenech, Josep Maria — Mayo Clinic Rochester
- Study coordinator: Domingo-Domenech, Josep Maria
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.